Wednesday, April 26, 2023, San Antonio, Texas, 6:00 PM – 8:00 PM Central Time (7:00 PM – 9:00 PM Eastern Time)

What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation

Fifteenth Annual RTP Symposium Series Held During the Annual ONS Congress

Breast Cancer

 
Location
Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — Dinner Meeting

Meeting Room
Texas Ballroom (Salons A-C) – Fourth Floor


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Jamie Carroll, APRN, MSN, CNP
Mayo Clinic
Rochester, Minnesota

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas


Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas

Ronald Stein, JD, MSN, NP-C, AOCNP
Clinical Instructor of Medicine
USC Norris Comprehensive Cancer Center
Los Angeles, California

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Exact Sciences Corporation, Lilly, Merck, Puma Biotechnology Inc, Seagen Inc, and TerSera Therapeutics LLC during the Oncology Nursing Society’s (ONS) 48th Annual Congress, April 26–30, 2023 in San Antonio, Texas. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.
Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — Educational Dinner Meeting

What I Tell My Patients About ...

Neoadjuvant and Adjuvant Therapy for Localized HER2-Positive Breast Cancer

  • Clinical factors affecting the decision to administer neoadjuvant and adjuvant systemic treatment for HER2-positive localized breast cancer; selection of appropriate regimens
  • Published clinical research findings with postadjuvant neratinib for HER2-positive localized breast cancer
  • Improved rates of CNS recurrence with extended adjuvant neratinib
  • Clinical and biologic factors, such as hormone receptor (HR) status and extent of disease, influencing patient selection for treatment with postadjuvant neratinib

Available Therapies for HER2-Positive Metastatic Breast Cancer (mBC)

  • Clinical factors affecting the selection and sequencing of therapy for HER2-positive mBC, such as prior HER2-directed therapy, symptomatology, disease-free interval and sites and extent of metastases
  • Long-term results with tucatinib/trastuzumab/capecitabine for HER2-positive mBC
  • Findings from key studies evaluating trastuzumab deruxtecan (T-DXd) for HER2-positive mBC; implications for therapeutic sequencing
  • Published data with neratinib/capecitabine for HER2-positive mBC
  • Key considerations in the treatment of HER2-positive brain metastases

New Treatment Options for HER2-Low mBC

  • Incidence and clinical characteristics of HER2-low breast cancer
  • Biologic explanation for the antitumor activity of T-DXd for HER2-low disease
  • Recently published findings supporting the use of T-DXd for previously treated, HER2-low advanced breast cancer
  • Optimal sequencing of T-DXd in relation to other available therapies for HR-positive or HR-negative, HER2-low mBC

The Incidence and Management of Toxicities with T-DXd for Breast Cancer

  • Risk factors for and reported incidence and severity of interstitial lung disease (ILD) and pneumonitis with T-DXd for breast cancer
  • Strategies to manage ILD and pneumonitis associated with T-DXd; indications for restarting T-DXd after resolution of symptoms
  • Spectrum, incidence, severity and management of other toxicities reported with T-DXd

The Tolerability of HER2-Targeted Tyrosine Kinase Inhibitors (TKIs) Used in the Treatment of Breast Cancer

  • Similarities and differences among available HER2-targeted TKIs such as neratinib, tucatinib and lapatinib; implications for the incidence and severity of class-related and agent-specific toxicities
  • Frequency and severity of gastrointestinal (GI) side effects, such as diarrhea and vomiting, with HER2-targeted TKIs
  • Dose-escalation and other available approaches to mitigate neratinib-associated GI toxicities
  • Spectrum of other clinically relevant toxicities related to TKIs, including rash and hepatotoxicity; optimal monitoring and management strategies

The Utility of Genomic Assays in Treatment Decision-Making for ER-Positive, HER2-Negative Localized Breast Cancer

  • Clinicopathologic factors affecting risk of recurrence and the decision to consult a genomic assay for patients with ER-positive, HER2-negative localized breast cancer
  • Major clinical trial findings defining the role of chemotherapy in premenopausal and postmenopausal patients with ER-positive, HER2-negative localized breast cancer with 1 to 3 positive lymph nodes and a 21-gene Recurrence Score© (RS) ≤25
  • Other recent studies informing the use of the 21-gene RS to guide neoadjuvant and adjuvant treatment
  • Practical interpretation of genomic assay results and implications for therapeutic decision-making

Adjuvant Endocrine Therapy for ER-Positive Localized Breast Cancer

  • Impact of age and menopausal status on the selection of adjuvant endocrine therapy; rationale for the addition of ovarian function suppression (OFS)/ablation to standard hormonal therapy for premenopausal patients
  • Optimal timing of initiation and duration of OFS for patients with breast cancer receiving cytotoxic therapy
  • Counseling premenopausal patients who are about to undergo cytotoxic therapy about its potential gonadotoxic effects and available strategies to preserve fertility and/or prevent premature ovarian insufficiency
  • Monitoring for and prevention and management of adverse events (AEs) with OFS

The Role of CDK4/6 Inhibitors in Therapy for Localized ER-Positive Breast Cancer

  • Key findings with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative breast cancer who are at high risk for recurrence
  • Guideline-endorsed indications for adjuvant abemaciclib; identification of appropriate candidates for this strategy
  • Comparative tolerability of abemaciclib in the adjuvant and metastatic settings; appropriate threshold for dose reduction or delays or treatment discontinuation for patients with breast cancer undergoing potentially curative therapy
  • Emerging findings with the use of ribociclib as a component of adjuvant therapy; potential clinical implications

Currently Available Therapies for ER-Positive mBC

  • Factors affecting the selection of a CDK4/6 inhibitor and an endocrine partner as first-line treatment
  • Prevalence of PIK3CA mutations in ER-positive mBC; published research findings with alpelisib/fulvestrant for this disease
  • Pivotal findings with the oral selective estrogen receptor downregulator (SERD) elacestrant for patients with ER-positive mBC
  • Integration of elacestrant into the current management of ER-positive mBC; importance of ESR1 testing to identify appropriate candidates

The Role of PARP Inhibitors in the Management of Breast Cancer

  • Frequency and clinical significance of BRCA and other mutations in DNA damage repair pathways in breast cancer; recommended approach to testing
  • Key findings, including overall survival outcomes, with adjuvant olaparib for high-risk, HER2-negative breast cancer with germline BRCA1/2 mutations
  • Guideline-endorsed indications for adjuvant olaparib; identification of proper candidates for this approach
  • Long-term data guiding the optimal use of PARP inhibitors for HER2-negative mBC with germline BRCA mutations

The Tolerability of PARP Inhibitors for Patients with Breast Cancer

  • Incidence, timing and severity of common class- and agent-specific toxicities associated with PARP inhibitors for breast cancer
  • Risk of long-term, serious side effects with PARP inhibitor therapy, such as acute myeloid leukemia and myelodysplastic syndromes
  • Optimal monitoring and management paradigm, including dose-modification strategies, for PARP inhibitor-related toxicities

The Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer (TNBC)

  • Recommended approaches to PD-L1 assessment for TNBC
  • Major findings with neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for high-risk localized TNBC
  • Selection of appropriate patients with localized TNBC for (neo)adjuvant pembrolizumab therapy
  • Key clinical research guiding the optimal use of pembrolizumab/chemotherapy for PD-L1-positive metastatic TNBC

The Tolerability of Immune Checkpoint Inhibitors for Patients with TNBC

  • Pathophysiology, incidence and spectrum of immune-mediated and other AEs observed with anti‑PD‑1/PD-L1 antibodies
  • Optimal monitoring and management paradigm for immune-related and other AEs associated with immune checkpoint inhibitors for TNBC; differences in approach, if any, for localized versus metastatic disease
  • Relative and absolute contraindications to anti-PD-1/PD-L1 antibody therapy; role, if any, for patients with TNBC and preexisting autoimmune complications

Promising Investigational Strategies in Breast Cancer Management

  • Educating patients regarding the potential advantages of participating in a clinical research study
  • Mechanism of action of capivasertib; efficacy and safety of capivasertib/fulvestrant compared to placebo/fulvestrant for recurrent ER-positive, HER2-negative mBC
  • Available data with and ongoing evaluation of next-generation oral SERDs beyond elacestrant (eg, camizestrant, imlunestrant) for ER-positive, HER2-negative mBC
  • Novel antibody-drug conjugates under investigation for mBC, such as datopotamab deruxtecan, patritumab deruxtecan and ladiratuzumab vedotin

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand published research data guiding the selection and duration of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Discuss with patients the risks and benefits of various anti-HER2 therapies used in the long-term management of HER2-positive metastatic breast cancer (mBC).
  • Understand the clinical relevance of and current management approaches for HER2-low mBC.
  • Consider how the results of genomic assays are applied to personalize adjuvant systemic therapy for newly diagnosed ER-positive breast cancer.
  • Comprehend available clinical trial findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the optimal role of these agents as adjuvant treatment.
  • Counsel patients about the selection and sequencing of systemic therapy for ER-positive mBC.
  • Review published research documenting the benefit of chemotherapy in combination with anti‑PD‑1/PD-L1 antibodies for newly diagnosed localized or metastatic triple-negative breast cancer, and use this information to educate patients.
  • Appraise published efficacy and safety data with PARP inhibitors for patients with breast cancer harboring BRCA1/2 mutations.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 2 contact hours is provided by RTP.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. https://www.researchtopractice.com/Meetings/ONS2023/Breast/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ms CarrollAdvisory Committee: Lilly, Pfizer Inc, Sanofi, Sermonix Pharmaceuticals. Dr KaklamaniConsulting Agreements: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Puma Biotechnology Inc, TerSera Therapeutics LLC; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc, Seagen Inc. Dr O’ShaughnessyAdvisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Fishawack Health, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, GSK, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Ontada, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Synthon, Theralink, Veru; Nonrelevant Financial Relationship: prIME Oncology. Mr SteinAdvisory Committee: AstraZeneca Pharmaceuticals LP.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Exact Sciences Corporation, Lilly, Merck, Puma Biotechnology Inc, Seagen Inc, and TerSera Therapeutics LLC.

Grand Hyatt San Antonio River Walk
600 E Market Street
San Antonio, TX 78205
Hotel Phone: (210) 224-1234

Meeting Room:
Texas Ballroom (Salons A-C) – Fourth Floor

The Grand Hyatt San Antonio is the headquarters hotel for the 2023 ONS Congress and is conveniently connected to the Henry B González Convention Center.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

​ ​
IN-PERSON registration
Thank you for your interest in our NCPD program taking place in San Antonio, Texas. At this time online preregistration for in-person is closed for this event. LIMITED SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 5:30 PM Central Time on Wednesday, April 26th. If you are interested in attending, please visit our registration desk located outside the Texas Ballroom (Salons A-C) – Fourth Floor of the Grand Hyatt San Antonio River Walk hotel which is connected to the Henry B Gonzalez Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com.

Please note, onsite registration does not guarantee seating and participation in meal service and will be based on availability.

LIVE WEBCAST registration open to all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.